

1/25




Fig. 1a

BEST AVAILABLE COPY

2/25




Fig. 1b

3/25




Fig. 1c

BEST AVAILABLE COPY

4/25




Fig. 1d

5/25




Fig. 1e

BEST AVAILABLE COPY

6/25




Fig. 1f

BEST AVAILABLE COPY

7/25




Fig. 1g

BEST AVAILABLE COPY

8/25




Fig. 2a

9/25




Fig. 2b

BEST AVAILABLE COPY

10/25




Fig. 3

11/25




Fig. 4a

BEST AVAILABLE COPY

12/25




Fig. 4b






Fig. 4c

14/25




Atorvastatin




Lovastatin

Fig. 5a

15/25




Pravastatin Sodium




Fluvastatin

Fig. 5b

16/25



Mevastatin



Simvastatin

Fig. 5c

Ragi cells
IFN- γ /Simva
L-Mevalonate
IFN- γ /Simva
IFN- γ /Atorva
IFN- γ /Lova
IFN- γ /Prava
IFN- γ
Control




Fig. 6

BEST AVAILABLE COPY





Fig. 7

BEST AVAILABLE COPY



* $p < 0.02$ ** $p < 0.05$

1 Control
2 rCD40L (5 μ g/ml)
3 rCD40L + pravastatin (5 μ M)
4 rCD40L + lovastatin (5 μ M)
5 rCD40L + atorvastatin (5 μ M)
6 rCD40L + simvastatin (5 μ M)
7 rCD40L + simvastatin (5 μ M) + L-Mevalonate (200 μ M)

Fig. 8

BEST AVAILABLE COPY

20/25





Fig. 9a

21/25

Statin treatment



CD40L staining

Fig. 9b

BEST AVAILABLE COPY





Fig. 9c

23/25

Day 10 after Tx



Day 14 after Tx





Fig. 10

Day 6 after onset of arthritis



Day 12 after onset of arthritis




Fig. 11

	³ H] Thymidine incorporation [cpm]	IFN- γ production [pg/ml]
Control	13,830 (\pm 7,078)	60,112 (\pm 13,532)
Low dose	6,508 (\pm 6,499) *	36,368 (\pm 8,005) *
High dose	5,221 (\pm 7,632) *	29,805 (\pm 8,114) *

Fig. 12